BIOMERICA INC
For the period ended Aug 31, 2026. Filed Oct 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Aug 31, 2026 · Filed Oct 15, 2026
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
**FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2026 **or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number:001-37863
BIOMERICA, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 95-2645573 |
|---|---|
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| 17571 Von Karman Avenue, Irvine, CA | 92614 |
|---|---|
| (Address of principal executive offices) | (Zip Code) |
(949) 645-2111
(Registrant’s telephone number, including area code)
Securities registered under Section 12(b) of the Exchange Act:
| Title of each class | Trading Symbols | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.08 per share | BMRA | Nasdaq Capital Market |
Indicate by check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (paragraph 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company**,**” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Non-accelerated filer ☒ | Smaller reporting company ☒ |
| Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act).
Yes ☐ No☒
The number of shares of the registrant’s common stock outstanding as of October 15, 2026 was 4,598,968.
BIOMERICA, INC.
INDEX
| PART I · Financial Information | ||
|---|---|---|
| Item 1. · Financial Statements: | ||
| Condensed Consolidated Balance Sheets – August 31, 2026 (unaudited) and May 31, 2026 | 1 | |
| Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) – Three Months Ended August 31, 2026 and August 31, 2025 | 2 | |
| Condensed Consolidated Statements of Shareholders’ Equity (unaudited) – Three Months Ended August 31, 2026 and August 31, 2025 | 3 | |
| Condensed Consolidated Statements of Cash Flows (unaudited) – Three Months Ended August 31, 2026 and August 31, 2025 | 4 | |
| Notes to Condensed Consolidated Financial Statements (unaudited) | 5 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 17 |
| Item 3. | Quantitative and Qualitative Disclosures about Market Risk | 25 |
| Item 4. | Controls and Procedures | 25 |
| PART II | Other Information | 26 |
| Item 1. | Legal Proceedings | 26 |
| Item 1A. | Risk Factors | 26 |
| Item 5. | Other Information | 26 |
| Item 6. | Exhibits | 26 |
| Signatures | 27 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.